Back to Browse Journals » Cancer Management and Research » Volume 4

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma

Authors Fisher R, Larkin J

Published Date August 2012 Volume 2012:4 Pages 243—252

DOI http://dx.doi.org/10.2147/CMAR.S25284

Received 6 May 2012, Accepted 20 June 2012, Published 8 August 2012

Rosalie Fisher, James Larkin

Department of Medical Oncology, Royal Marsden Hospital, London, United Kingdom

Abstract: The BRAF inhibitor, vemurafenib, has demonstrated improved progression-free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care in patients with advanced melanoma harboring a BRAF-V600 mutation. A BRAF-V600 mutation is identified in approximately half of patients with cutaneous melanoma, and is unequivocally a biomarker predictive of profound clinical benefit for these patients. However, acquired vemurafenib resistance is a major clinical challenge and therapy is not yet curative. A substantial body of translational research has been performed alongside clinical trials of vemurafenib, providing key insights into the molecular basis of response and resistance. This review summarizes the development of vemurafenib for the treatment of BRAF-V600 mutant melanoma and discusses how knowledge of critical signaling pathways will be applied for its optimal clinical use in future.

Keywords: vemurafenib, melanoma, BRAF-V600, BRIM-3

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read: